What is HC Wainwright's Forecast for DYN FY2028 Earnings?

Key Points

• HC Wainwright lowered its FY2028 EPS forecast for Dyne Therapeutics to a loss of $1.98 per share from $1.91, while maintaining a “Buy” rating and a $32 price target. The firm projects losses of $0.65 per share in FY2029 before profitability of $1.03 per share in FY2030.
• Analyst sentiment remains broadly positive, with Dyne carrying a “Moderate Buy” consensus rating and an average price target of $33.07, despite recent target reductions and competitive concerns surrounding its DM1 programs.
• Dyne’s latest quarterly results missed expectations, reporting a loss of $1.08 per share versus the consensus loss estimate of $0.75. Shares opened at $15.82, well below the 52-week high of $27.31, while institutional investors own 96.68% of the stock.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Equities researchers at HC Wainwright dropped their FY2028 EPS estimates for shares of Dyne Therapeutics in a note issued to investors on Wednesday, September 30th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings of ($1.98) per share for the year, down from their previous forecast of ($1.91). HC Wainwright has a "Buy" rating and a $32.00 price target on the stock. The consensus estimate for Dyne Therapeutics' current full-year earnings is ($3.59) per share. HC Wainwright also issued estimates for Dyne Therapeutics' FY2029 earnings at ($0.65) EPS and FY2030 earnings at $1.03 EPS.

Other analysts have also issued research reports about the stock. Stifel Nicolaus set a $37.00 price target on shares of Dyne Therapeutics in a research note on Wednesday. Jefferies Financial Group reissued a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Wednesday. Cantor Fitzgerald reissued a "buy" rating on shares of Dyne Therapeutics in a research report on Wednesday. TD Cowen initiated coverage on shares of Dyne Therapeutics in a research note on Friday, June 26th. They issued a "buy" rating on the stock. Finally, Royal Bank Of Canada decreased their price target on Dyne Therapeutics from $35.00 to $30.00 and set an "outperform" rating for the company in a research note on Wednesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $33.07.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $15.82 on Friday. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics has a fifty-two week low of $12.33 and a fifty-two week high of $27.31. The business has a 50 day moving average price of $22.70 and a two-hundred day moving average price of $20.59. The firm has a market cap of $2.95 billion, a PE ratio of -4.75 and a beta of 1.13.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.33).

Hedge Funds Weigh In On Dyne Therapeutics

Large investors have recently made changes to their positions in the business. Hilton Head Capital Partners LLC acquired a new stake in Dyne Therapeutics during the first quarter valued at approximately $26,000. Allworth Financial LP bought a new position in shares of Dyne Therapeutics in the second quarter valued at $62,000. Nykredit A S acquired a new stake in shares of Dyne Therapeutics during the 2nd quarter valued at $113,000. Keating Financial Advisory Services Inc. bought a new stake in shares of Dyne Therapeutics during the 2nd quarter worth $114,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Dyne Therapeutics in the 2nd quarter worth $124,000. Institutional investors own 96.68% of the company's stock.

Insider Activity at Dyne Therapeutics

In related news, insider Douglas Kerr sold 3,745 shares of Dyne Therapeutics stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $24.35, for a total transaction of $91,190.75. Following the sale, the insider directly owned 163,854 shares in the company, valued at $3,989,844.90. The trade was a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Cox sold 5,658 shares of the company's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the sale, the chief executive officer owned 357,507 shares of the company's stock, valued at $6,749,732.16. This trade represents a 1.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 3,376,157 shares of company stock worth $83,290,469 in the last three months. 9.46% of the stock is owned by company insiders.

More Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Encouraging one-year DM1 data: Dyne reported that DYNE-101, also known as z-basivarsen, continued to show functional improvements after one year in its DM1 study. The results support the potential durability of the company’s targeted delivery platform and helped drive buying interest in the shares. Dyne Reports One-Year DM1 Trial Improvements
• Positive Sentiment: Analysts remain bullish: Chardan Capital reaffirmed its “buy” rating and set a $38 price target, while HC Wainwright maintained a “buy” rating despite lowering its target to $32 from $50. The targets imply substantial upside if Dyne’s clinical programs meet expectations. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Positive data may be partly reflected in the stock: Reports described the DM1 results as a reason for shares to rise, but investors are likely seeking additional evidence on the size, durability and safety of the treatment benefit before assigning a higher valuation. Dyne Therapeutics stock rises on positive DM1 trial results
• Negative Sentiment: Competitive pressure remains the main risk: A rival’s DM1 data contributed to Dyne’s recent decline, raising questions about the company’s competitive position and making a “buy-the-dip” strategy speculative rather than low risk. HC Wainwright’s target reduction also reflects more cautious expectations. Dyne Recent Price Drop on Rival’s DM1 Data

About Dyne Therapeutics

Dyne Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing genetic medicines for serious neuromuscular diseases. The company's research is centered on its FORCE platform, which is designed to use targeted antibodies to deliver oligonucleotide-based therapies to skeletal muscle and other relevant tissues.

Dyne's development programs include DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.